CN106074540B - A kind of pharmaceutical composition and its application for hyperuricemia treatment - Google Patents
A kind of pharmaceutical composition and its application for hyperuricemia treatment Download PDFInfo
- Publication number
- CN106074540B CN106074540B CN201610401518.5A CN201610401518A CN106074540B CN 106074540 B CN106074540 B CN 106074540B CN 201610401518 A CN201610401518 A CN 201610401518A CN 106074540 B CN106074540 B CN 106074540B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- puerarin
- group
- hyperuricemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 53
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 39
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 239000000470 constituent Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002961 anti-hyperuricemic effect Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 30
- 201000005569 Gout Diseases 0.000 abstract description 27
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 26
- 229940116269 uric acid Drugs 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000007812 deficiency Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000011552 rat model Methods 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 239000000843 powder Substances 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 238000003304 gavage Methods 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 235000019890 Amylum Nutrition 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- -1 is uniformly mixed Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- AKQOBHZKBDHWQI-BZEFIUHZSA-N O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O Chemical compound O[C@H]1C[C@@H](CCC1)N1C(C2(C3=C1N=C(N=C3)NC1=CC=C(C=C1)S(=O)(=O)NC([2H])([2H])[2H])CC2)=O AKQOBHZKBDHWQI-BZEFIUHZSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000001509 acute urate nephropathy Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940127108 compound 5g Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- FWQHRZXEQNUCSY-UHFFFAOYSA-N tert-butyl N-[2-(ethoxycarbonylamino)-5-[(4-fluorophenyl)methyl-prop-2-ynylamino]phenyl]carbamate Chemical compound CCOC(=O)NC1=C(C=C(C=C1)N(CC#C)CC2=CC=C(C=C2)F)NC(=O)OC(C)(C)C FWQHRZXEQNUCSY-UHFFFAOYSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition for hyperuricemia treatment and its applications, belong to pharmaceutical technology field.In order to overcome existing treatment hyperuricemia side effects of pharmaceutical drugs larger, the technical deficiency that therapeutic effect is not good enough, present invention offer is a kind of to treat hyperuricemia pharmaceutical composition, is made of type I compound and Puerarin.Two kinds of active constituents of medicine have significant synergistic effect in terms of the arthroncus for inhibiting gout rat model and in terms of reducing blood uric acid value, to play good therapeutic effect to hyperuricemia.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for hyperuricemia treatment and its applications, belong to medical science neck
Domain.
Background technology
Hyperuricemia refers to that the lithate of extracellular fluid is in over-saturation state, as male's blood urine hydrochlorate >=416umol/
L, and it is considered as hyperuricemia when women >=357umol/L.Hyperuricemia is divided into primary and secondary two major classes, former
Hair property hyperuricemia is generated to increase or drain reduction or the two simultaneously and deposit by uric acid and is led to.Gout is urate crystals deposition
Caused clinical syndrome, be the arthritis that recurrent exerbation is shown as using hyperuricemia as main feature, tophus formed and
Joint deformity, arteriosclerotic kidney and uric acid nephrolithiasis can be caused by involving kidney, severe patient may occur in which joint disable, kidney function
It can not be complete.Therefore, anti-trioxypurine treatment is very important.Gout is hair caused by purine metabolic disturbance and underexcretion
Sick rate increases year by year.The incidence of various countries is different, and nearly 10 annual morbidity in Asia is gradually increasing.Foreign data shows the high urine of adult
The incidence of acidaemia is up to 5%, and the illness rate of gout is up to 0.13% -0.37%.As our people's people life is horizontal not
Disconnected to improve, the dietary structure of people has a very big change, high purine, high protein, high in fat.Into 21st century, goat has become
The second largest metabolic disease of the mankind after diabetes.Clinical characters are：Hyperuricemia, acute arthritis recurrent exerbation, pain
The formation of wind stone, chornic arthritis and joint deformity, and there is calculus urate and gouty parenchymal lesion of the kidney in the course of disease later stage.
It is acute gouty arthritis that this disease, which has generally been mainly in family history 30 years old or more male, clinical manifestation,：More nights and close to daybreak prominent
Hair, affected joints and big toe；Kidney stone and nephrosis can also be caused：Kidney calculus urate obstruction urinary system causes renal colic and blood
Urine, most of patients have renal hypertension and albuminuria, minority that can develop into renal failure.Gout has become 21st century
New urgency that the whole world faces one of disease to be controlled.
Therapeutically, the Pathological Physiology machine that high lithemia disease medicine or gout suppressant occur mainly for gout
System can play antigout effect by inhibiting uric acid synthesis, promoting uric acid excretion or inhibiting inflammatory reaction.Gout acute attack
Treatment mainly to use non-salicylic acid non-steroidal anti-inflammatory drugs and colchicin, the purpose of primary treatment of chronic gout be to reduce blood
Middle uric acid content commonly uses probenecid and Allopurinol etc..However, these drugs are because offer limited effectiveness, adverse reaction are larger and clinical
Using limited.Therefore, it clinically there is no ideal gout treatment drug.Traditional hyperuricemia therapeutic modality operation, radiotherapy,
Chemotherapy is all the western medical treatment method of hyperuricemia.Often all there is side effect in the treatment of doctor trained in Western medicine.Operation is for antihyperuricemic
The loss of disease patient body is very big, is easy to keep originally weak patient body weaker, body slow so as to cause post-operative recovery
Interior remaining cancer cell more fast-growth.Chemicotherapy is changed using the radioactive ray to hyperuricemia cell with killing effect
Drug is learned, is the therapeutic modality of " combatting poison with poison ".But chemicotherapy can be immunized human normal thin while killing cancer cell
Born of the same parents, normal organ also result in certain injury, Nausea and vomiting occur, without symptoms such as appetite, alopecias, these are all western medical treatments
Side effect.
Chinese invention patent ZL201210122406.8 disclose one group can be used for adjust blood uric acid levels compound,
Contain its composite and its application method.In some embodiments, compound of the present invention is for treating or preventing and urinating
The related illness of sour horizontal abnormality.Wherein the compound includes type I compound of the present invention, but in use
The toxic side effect of the drug is still very big.Chinese medicine has accumulated abundant experience and theory in terms for the treatment of hyperuricemia, and makees
Traditional Chinese medicine monomer drug for modern Chinese herbal medicine development is even more to cause to study this huge interest.The poison of these traditional Chinese medicine monomer drugs is secondary
Act on it is relatively low, and act on more fully.The invention reside in provide the antihyperuricemic that a kind of therapeutic effect is notable and side effect is smaller
Disease medicine..
Invention content
In order to overcome existing treatment hyperuricemia side effects of pharmaceutical drugs larger, the technical deficiency that therapeutic effect is not good enough, this
Invention offer is a kind of to treat hyperuricemia pharmaceutical composition, is made of type I compound and Puerarin.Two kinds of pharmaceutical activity at
Point there is significant synergistic effect in terms of the arthroncus for inhibiting gout rat model and in terms of reducing blood uric acid value, to right
Hyperuricemia plays good therapeutic effect.
To achieve the goals above, present invention employs following technical schemes：
A kind of pharmaceutical composition for treating hyperuricemia, is made of following active constituent：
1) type I compound；
2) Puerarin.The structural formula of wherein type I compound is
。
Type I compound and the weight ratio of Puerarin are 1 wherein in described pharmaceutical composition：0.1-10, more preferably 1：5.
The present invention also provides a kind of pharmaceutical preparations for treating hyperuricemia, it is by a effective amount of type I compound, has
The preparation that the Puerarin of effect amount and pharmaceutically acceptable auxiliary material or complementary ingredient are prepared.Wherein, the drug system
Agent is oral preparation.The oral preparation is preferably its capsule, tablet, granule.
In the pharmaceutical preparation for the treatment of hyperuricemia described above, the content of Puerarin is 1- in each preparation unit
2000mg。
The present invention is also claimed aforementioned pharmaceutical compositions and is preparing the purposes in treating antihyperuricemic disease drug.The present invention
Embodiment 7 shows that type I compound list medicine group, Puerarin list medicine group all inhibit arthroncus to a certain extent, and compound each group can
To significantly inhibit rat articular swelling degree, and though for arthroncus inhibiting effect compared with Puerarin list medicine group or
The difference of conspicuousness is all had compared with type I compound list medicine group, and two kinds of drugs is prompted to have in terms of inhibiting rat articular swelling
There is significant synergistic effect.The blood uric acid value of model group difference with conspicuousness compared with normal group simultaneously, modeling success.Formula
I compound list medicine group, Puerarin list medicine group can all reduce the blood uric acid value of Gout Model to a certain extent, and compound each group can
To significantly reduce the blood uric acid value of Gout Model, no matter reducing the degree and Puerarin list medicine group of the blood uric acid value of Gout Model
Compared to the difference for still all having conspicuousness compared with type I compound list medicine group, two kinds of drugs is prompted to reduce Gout Model
There is significant synergistic effect in terms of blood uric acid value.
The present invention has following unexpected technique effect outstanding compared with prior art：
1）Type I compound list medicine group, Puerarin list medicine group all inhibit arthroncus to a certain extent, and compound each group can be with
Significantly inhibit rat articular swelling degree, and though for arthroncus inhibiting effect compared with Puerarin list medicine group or with
Type I compound list medicine group compares the difference for all having conspicuousness, and two kinds of drugs is prompted to have in terms of inhibiting rat articular swelling
Significant synergistic effect.
2）Type I compound list medicine group, Puerarin list medicine group can all reduce the blood uric acid of Gout Model to a certain extent
Value, compound each group can significantly reduce the blood uric acid value of Gout Model, no matter reducing the degree of the blood uric acid value of Gout Model
The difference of conspicuousness is all had compared with Puerarin list medicine group or compared with type I compound list medicine group, two kinds of drugs is prompted to exist
There is significant synergistic effect in terms of reducing the blood uric acid value of Gout Model.
3）The two can significantly reduce the dosage of type I compound while therapeutic effect enhances after being used in combination,
To reduce its drug risk, its drug safety is improved.
Specific implementation mode
The present invention is further described by the following examples, but these embodiments are illustrative of the invention, and should not be understood
For any limitation on the scope of the present invention.
The preparation of 1 composite tablet of embodiment
| Puerarin | 1g |
| Type I compound | 10g |
| Microcrystalline cellulose | 45g |
| Starch | 30g |
| 15% starch slurry | In right amount |
| Magnesium stearate | 2.0g |
Preparation process：Puerarin and type I compound are uniformly mixed with microcrystalline cellulose excipients, starch, are added suitable
Then 15% starch slurry softwood crosses the sieve granulation of 16 mesh.Wet granular crosses 16 mesh sieves, sifts out dry granular in 60 DEG C of dryings, dry particl
In fine powder, and magnesium stearate mixing, then again with dry particl mixing, tabletting to get.
The preparation of 2 composite tablet of embodiment
| Puerarin | 10g |
| Type I compound | 1g |
| Amylum pregelatinisatum | 90g |
| Lactose | 50g |
| 15% starch slurry | In right amount |
| Superfine silica gel powder | 1.5g |
Preparation process：In addition to component is different, preparation process is the same as technique described in embodiment 1.
The preparation of 3 compound dispersed tablet of embodiment
| Puerarin | 10g |
| Type I compound | 2g |
| Croscarmellose sodium | 12g |
| Microcrystalline cellulose | 160g |
| Polyvinylpyrrolidone | 6g |
| 60% ethanol solutions of 5%PVP | In right amount |
| Superfine silica gel powder | 5g |
Preparation process：Puerarin, type I compound are weighed by recipe quantity, using microcrystalline cellulose as filler, cross-linked carboxymethyl
Sodium cellulosate, polyvinylpyrrolidone are disintegrant, and 60% ethanol solutions of 5%PVP are binder, and superfine silica gel powder is glidant,
With fluid-bed marumerization, then tabletting to get.
The preparation of 4 composite tablet of embodiment
| Puerarin | 50g |
| Type I compound | 5g |
| Amylum pregelatinisatum | 90g |
| Lactose | 50g |
| 15% starch slurry | In right amount |
| Superfine silica gel powder | 1.5g |
Preparation process：It is prepared by technique described in embodiment 2 to obtain the final product.
The preparation of 5 compound granule of embodiment
| Puerarin | 40g |
| Type I compound | 8g |
| Starch | 180g |
| Dextrin | 50g |
| Cane sugar powder | 60g |
| 80% ethyl alcohol | In right amount |
Preparation process：Puerarin, type I compound, starch, dextrin, the cane sugar powder for weighing recipe quantity are uniformly mixed.It will separately fit
80% ethyl alcohol of amount is incorporated in mixed-powder, is uniformly mixed, wet grain, 60 DEG C of left and right trunks are made by 18 mesh nylon mesh in softwood processed
It is dry, 20 mesh sieves, packing to get.
The preparation of 6 compound granule of embodiment
| Puerarin | 50g |
| Type I compound | 50g |
| Starch | 180g |
| Dextrin | 50g |
| Cane sugar powder | 60g |
| 80% ethyl alcohol | In right amount |
Preparation process：Puerarin, starch, dextrin, the cane sugar powder for weighing recipe quantity are uniformly mixed.Separately by suitable 80% second
Alcohol is incorporated in mixed-powder, is uniformly mixed, softwood processed, and wet grain, 60 DEG C or so dryings, 20 mesh sieve is made by 18 mesh nylon mesh
Whole grain, packing to get.
Shadow of 7 pharmaceutical composition of the present invention of embodiment to inhibiting effect and blood uric acid to Gout Model rat articular swelling
It rings
1, animal model and administration
It is the male rat 60 of 200 ~ 220 g to take weight, adapts to weigh after 5 d of laboratory, number, is randomly divided into
It 9 groups, every group 10, is administered once daily, 5 d of continuous gavage.Each administration group administrations are as follows：
Normal group and model group give normal saline.
Low group of type I compound：Gavage gives type I compound 0.5mg/kg;
High group of type I compound：Gavage gives type I compound 5mg/kg;
Low group of Puerarin：Gavage gives Puerarin 0.5mg/kg；
High group of Puerarin：Gavage gives Puerarin 5mg/kg；
1 group of compound：Gavage gives type I compound 0.5mg/kg+ Puerarins 5mg/kg；
2 groups of compound：Gavage gives type I compound 5mg/kg+ Puerarins 0.5mg/kg；
3 groups of compound：Gavage gives type I compound 0.5mg/kg+ Puerarins 2.5mg/kg.
Monosodium urate crystallization is prepared simultaneously:194 ml distilled water add 6 mlNaOH, boil and add 1 g uric acid, with dilute hydrochloric acid tune
PH 7. 2, stirring cooling, 4 DEG C of refrigerators preserve 24 h, remove supernatant, blot sediment moisture with filter paper, be put into
70 DEG C of 2 h of baking of drying box, take out, scrape powder, be put into pulverization in mortar, with the metal mesh of 250 mm of aperture
Sieve, sieving, bottling are spare.Used time takes the crystallization of 250 mg Monosodium urates plus 45 ml, 0.9% chloride injection solution, then adds 5m
L Tween 80s, heating stirring are made into 50ml uric acid sodium solutions.
Except normal group is outer, it is point of puncture that right Ankle lateral rear is selected per experimental mouse, needle mouth inclined-plane towards front upper place and
Shin bone penetrates ankle-joint chamber in angle of 45 degrees, 0. 2m l uric acid sodium solutions is injected to articular cavity with No. 4 syringe needles, with capsular ligament
Offside is heaved for injection standard, induction Gout Model.5 d (make each group rat after 3 h, and medication before modeling, after modeling
120h after mould) respectively in tested ankle-joint same area, with its diameter of vernier caliper measurement, observation modeling is front and back and medication
The tested joint diameter change of each group after treatment puts to death rat, abdominal aortic blood, 2 500 r/ in 2 h after the last administration
Min centrifuges 5 min, and serum is taken to measure uric acid level, carries out group difference and compares.
Inhibiting effect of 1 pharmaceutical composition of the present invention of table to rat articular swelling
Compared with Normal group, * * P ＜ 0.01, compared with model group,#P ＜ 0.05,##P ＜ 0.01；
Compared with type I compound list medicine group,▼P ＜ 0.05,▼▼P ＜ 0.01；Compared with Puerarin list medicine group,★P ＜ 0.05
,★★P ＜ 0.01；
As can be seen from Table 1, before modeling rat joint diameter do not have conspicuousness difference, 5h and 80h after modeling
The rat articular diameter of model group difference with conspicuousness compared with normal group.Type I compound list medicine group, Puerarin list medicine group
All inhibit arthroncus to a certain extent, compound each group can significantly inhibit rat articular swelling degree, for swollen joint
No matter swollen inhibiting effect all has the difference of conspicuousness compared with Puerarin list medicine group or compared with type I compound list medicine group
It is different, prompt two kinds of drugs that there is significant synergistic effect in terms of inhibiting rat articular swelling.
Influence of 2 pharmaceutical composition of the present invention of table to Gout Model Rats blood uric acid caused by Monosodium urate
| Group | Blood uric acid value |
| Normal group | 70.4±19.5 |
| Model group | 90.3±14.2** |
| Low group of type I compound | 84.3±8.5# |
| High group of type I compound | 78.3±9.5# |
| Low group of Puerarin | 86.4±7.2 |
| High group of Puerarin | 83.7±6.3# |
| 1 group of compound | 56.8±6.8##▼★ |
| 2 groups of compound | 42.9±5.4##▼▼★★ |
| 3 groups of compound | 33.3±7.4##▼▼★★ |
Compared with Normal group, * * P ＜ 0.01, compared with model group,#P ＜ 0.05,##P ＜ 0.01；
Compared with type I compound list medicine group,▼P ＜ 0.05,▼▼P ＜ 0.01；Compared with Puerarin group,★P ＜ 0.05,★★P
＜ 0.01；
As can be seen from Table 2, the blood uric acid value of model group difference with conspicuousness compared with normal group, modeling success.
Type I compound list medicine group, Puerarin list medicine group can all reduce the blood uric acid value of Gout Model, compound each group to a certain extent
The blood uric acid value of Gout Model can be significantly reduced, no matter reducing the degree and Puerarin list medicine of the blood uric acid value of Gout Model
Group prompts two kinds of drugs reducing Gout Model compared to the difference for still all having conspicuousness compared with type I compound list medicine group
Blood uric acid value in terms of there is significant synergistic effect.
Claims (6)
1. a kind of pharmaceutical composition for hyperuricemia treatment is made of following active constituent：
1) type I compound；
2) Puerarin；The structural formula of wherein type I compound is：
Type I compound and the weight ratio of Puerarin are 1 in described pharmaceutical composition：0.1-
10。
2. pharmaceutical composition according to claim 1, which is characterized in that type I compound and Pueraria lobota in described pharmaceutical composition
The weight ratio of root element is 1：5.
3. pharmaceutical composition according to claim 1 or 2, which is characterized in that described pharmaceutical composition is its oral preparation.
4. pharmaceutical composition according to claim 3, which is characterized in that the oral preparation of the pharmaceutical composition is it
Capsule, tablet or granule.
5. pharmaceutical composition according to claim 3, which is characterized in that the content of Puerarin is 1- in each preparation unit
2000mg。
6. pharmaceutical composition described in claim 1 is preparing the purposes in treating antihyperuricemic disease drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401518.5A CN106074540B (en) | 2016-06-10 | 2016-06-10 | A kind of pharmaceutical composition and its application for hyperuricemia treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610401518.5A CN106074540B (en) | 2016-06-10 | 2016-06-10 | A kind of pharmaceutical composition and its application for hyperuricemia treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106074540A CN106074540A (en) | 2016-11-09 |
| CN106074540B true CN106074540B (en) | 2018-10-16 |
Family
ID=57227543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610401518.5A Expired - Fee Related CN106074540B (en) | 2016-06-10 | 2016-06-10 | A kind of pharmaceutical composition and its application for hyperuricemia treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074540B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198513A (en) * | 1970-09-25 | 1980-04-15 | Merck & Co., Inc. | 1,2,4-Triazoles |
| WO2007050087A1 (en) * | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| CN101181287A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of puerarin in the preparation of uric acid transporter URAT1 inhibitory drugs |
| RS53569B1 (en) * | 2007-11-27 | 2015-02-27 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
-
2016
- 2016-06-10 CN CN201610401518.5A patent/CN106074540B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN106074540A (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN110301518A (en) | A kind of anti-trioxypurine pressed candy and preparation method thereof | |
| CN106074463A (en) | Cannabidiol application in preparation treatment gouty arthritis medicine | |
| CN101658519B (en) | Medicinal composition for treating hyperuricemia | |
| CN100431593C (en) | Chinese medicinal formulation for treating hydrocephalus | |
| CN104258051B (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN105287748B (en) | The Chinese materia medica preparation and preparation method thereof for treating hyperuricemia | |
| CN106074540B (en) | A kind of pharmaceutical composition and its application for hyperuricemia treatment | |
| CN115607588B (en) | Anti-gout apiary extract and non-bestatin pharmaceutical composition for treating both symptoms and root causes and application thereof | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| CN106139009B (en) | A kind of purposes of Chinese traditional medicine composition in the drug for preparing treatment chronic gout | |
| CN104800690B (en) | A kind of Chinese medicine of anti-trioxypurine and preparation method thereof | |
| CN108686102A (en) | A kind of Chinese medicine composition for treating gout | |
| CN109758497B (en) | Traditional Chinese medicine composition for chronic heart failure, medicine and preparation method and application thereof | |
| CN102813661B (en) | Application for glycyrrhetinic acid derivatives | |
| CN105362798A (en) | Traditional Chinese medicine for treating gouty arthritis and preparation method of traditional Chinese medicine | |
| CN105878263B (en) | Pharmaceutical composition containing Amicos (Banyu) and its application | |
| CN105832729A (en) | Pharmaceutical composition for treating hyperuricemia and application of pharmaceutical composition for treating hyperuricemia | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN105832757A (en) | Medicine composition with topiroxostat and application of medicine composition | |
| CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
| CN102406739B (en) | A kind of traditional Chinese medicine for treating hernia in children and its preparation method | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180903 Address after: 344000 70 building, A10 building, business incubation base, Fuzhou hi tech Industrial Development Zone, Fuzhou, Jiangxi, China. 2 Applicant after: Jiangxi Bofen Medical Devices Co.,Ltd. Address before: 266000 1 buildings in No. 713-1 Xiangjiang Road, Huangdao District, Qingdao, Shandong. Applicant before: QINGDAO KERUIYUAN BIOTECHNOLOGY CO.,LTD. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181016 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |